Is Shattuck Labs, Inc. overvalued or undervalued?

As of 9 November 2023, the valuation grade for Shattuck Labs, Inc. has moved from does not qualify to risky. The company appears to be overvalued given its financial metrics, particularly with a Price to Book Value of 0.81, an EV to EBIT of 0.07, and an EV to EBITDA of 0.08, indicating significant losses relative to its enterprise value. In comparison, peers such as Enzo Biochem, Inc. have a more negative EV to EBITDA of -0.1144, while BioXcel Therapeutics, Inc. shows an EV to EBITDA of -3.1146, suggesting that Shattuck Labs is not performing as well as some of its counterparts.
Despite a strong recent performance with a 1-month stock return of 118.63% compared to the S&P 500's 2.33%, the overall negative trends in longer-term returns, such as a 1-year decline of -38.9% versus the S&P 500's 17.14%, highlight the volatility and risks associated with this stock. Given these factors, Shattuck Labs, Inc. is considered overvalued in the current market context.